Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 13,632 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Melanoma (Skin)
Interventions: adenovirus RSV-TK, ganciclovir; Biological · Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 3
States / cities: Bethesda, Maryland • Houston, Texas

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Erythema, Rosacea
Interventions: AGN-199201, Vehicle to AGN-199201; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Lynchburg, Virginia

Conditions: Acne
Interventions: Doxycycline Anhydrous 40 MG, Adapalene/Benzoyl Peroxide Gel 0.3-2.5%; Drug
Lead sponsor: Derm Research, PLLC; Other
Eligibility: 12 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Psoriasis
Interventions: Cloderm Cream; Drug
Lead sponsor: Promius Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 5
States / cities: Cincinnati, Ohio • Portland, Oregon • Austin, Texas + 2 more

Conditions: Breast Cancer
Interventions: RECONJOINT; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Breast Cancer, Metastatic Breast Cancer
Interventions: Promoting Resilience in Women with Breast Cancer (PRISM); Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina

Conditions: Malignant Melanoma
Interventions: BMS-936558 (MDX1106-04), Ipilimumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 4
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • New York, New York + 1 more

Conditions: Breast Carcinoma Metastatic in the Bone, Circulating Tumor Cell Count, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Stage IV Breast Cancer
Interventions: Denosumab, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Chicago, Illinois • Lake Forest, Illinois

Conditions: Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions: PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo); Drug · Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more

Conditions: Malignant Neoplasm of Breast
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Irritable Bowel Syndrome
Interventions: DDP225; Drug
Lead sponsor: Dynogen Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 5
States / cities: Scottsdale, Arizona • St Louis, Missouri • Great Neck, New York + 2 more

Conditions: Metastatic Cancer, Metastatic Renal Cancer, Metastatic Melanoma
Interventions: PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes, Aldesleukin, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
Interventions: Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing; Other · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 16
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more

Conditions: Breast Cancer, Cervical Cancer
Interventions: CLS Intervention, No CLS intervention; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 21 Years and older · Female only
Enrollment: 1,025 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 3 more

Conditions: Foot Ulcer, Diabetic
Interventions: Engensis (VM202), Placebo; Genetic · Drug
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Radiation Therapy, Resection, Trotabresib, Vinorelbine; Procedure · Radiation · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: CA 15-3 Assay; Device
Lead sponsor: Fujirebio Diagnostics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Boca Raton, Florida • Fort Lauderdale, Florida • Wilmington, North Carolina

Conditions: Systemic Sclerosis
Interventions: RO7303509, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Palo Alto, California • New York, New York • Dallas, Texas

Conditions: Breast Cancer
Interventions: MKC-1; Drug
Lead sponsor: CASI pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer, Ulcer Foot, DFU
Interventions: SLAM + SOC, SOC; Other
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Clinton Township, Michigan

Conditions: Keratosis, Actinic
Interventions: Tirbanibulin ointment 1%; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 7
States / cities: Hot Springs, Arkansas • Encinitas, California • Sweetwater, Florida + 4 more

Conditions: Breast Cancer
Interventions: Partial Breast Irradiation; Radiation
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer

Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

The Use of Oracea and Epiduo Forte in Severe Acne Patients

Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis

A Study of a Decision Tool for People Considering Breast Reconstruction Surgery

Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

Ibrance Real World Insights

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Using a Lay Health Worker Program to Increase Breast and Cervical Cancer Screening in Low-Income Hispanic Women

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers

Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

A Prospective Longitudinal Breast Cancer Study

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis

A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1

Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care Versus Standard of Care

A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis

Partial Breast Irradiation in a Low-risk Population Screened With MRI